文献速递静脉血栓栓塞慢性静脉疾病

COVID-19 疫苗接种后血栓栓塞事件:286 例患者的系统综述

Thromboembolism after COVID-19 Vaccination: A Systematic Review of Such Events in 286 Patients.
PubMed 文献 · Ann Vasc Surg · 2022-05-11

该系统综述筛选 20 项研究,汇总 286 例 COVID-19 疫苗接种后血栓栓塞事件,静脉血栓(74.8%,n=214/286)多于动脉血栓(27.9%,n=80/286),脑静脉窦血栓最常见(28.3%,n=81/286),多发生于 AstraZeneca 疫苗后(93.7%),死亡占 29.9%。

要点

  • 静脉血栓(74.8%,n=214/286)较动脉血栓(27.9%,n=80/286)更常见。
  • 脑静脉窦血栓是最常见表现,占 28.3%(n=81/286)。
  • 血栓栓塞事件多报告于 AstraZeneca 疫苗后(93.7%),死亡占 29.9%。

核心结论

  • COVID-19 疫苗接种后可发生血栓栓塞事件,最常报告于 AstraZeneca 疫苗后,脑静脉窦血栓是接种者中最常见的表现。

研究设计与样本

  • 系统综述,系统筛选 COVID-19 疫苗接种后血栓栓塞事件的文献,最终纳入 20 项研究进行分析。

主要发现

  • 人群平均年龄 48.5±15.4 岁,女性占 67.4%,接种后至事件的平均时间为 10.8±7.2 天。
  • 静脉血栓占 74.8%(n=214/286),动脉血栓占 27.9%(n=80/286)。
  • 静脉血栓中以脑静脉窦血栓最常见(28.3%,n=81/286),其次为深静脉血栓(19.2%,n=49/254)。
  • 动脉血栓中以心肌梗死最常见(20.1%,n=55/274),其次为缺血性卒中(8.02%,n=22/274)。
  • 多部位并发血栓占 15.4%;血小板减少占 49%,抗血小板因子 4 抗体阳性占 78.6%;血栓栓塞事件多报告于 AstraZeneca 疫苗后(93.7%),死亡占 29.9%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Development of vaccines with high efficacy against COVID-19 disease has ushered a new ray of hope in the fight against the pandemic. Thromboembolic events have been reported after administration of vaccines. We aim to systematically review thromboembolic events reported after COVID-19 vaccination. METHODS: The available literature was systematically screened for available data on thromboembolic events after COVID-19 vaccination. Data were extracted from selected studies and analyzed for site of thromboembolism as well as other risk factors. All data were pooled to determine cumulative incidence of thromboembolism at various sites after vaccination. RESULTS: A total of 20 studies were selected for the final analysis. The mean age of the population was 48.5 ± 15.4 years (females - 67.4%). The mean time to event after vaccination was 10.8 ± 7.2 days. Venous thrombosis (74.8%, n = 214/286) was more common than arterial thrombosis (27.9%, n = 80/286). Cerebral sinus thrombosis was the most common manifestation (28.3%, n = 81/286) of venous thrombosis followed by deep vein thrombosis (19.2%, n = 49/254). Myocardial infarction was common (20.1%, n = 55/274) in patients with arterial thrombosis followed by ischemic stroke (8.02%, n = 22/274). Concurrent thrombosis at multiple sites was noted in 15.4% patients. Majority of patients had thrombocytopenia (49%) and antiplatelet factor 4 antibodies (78.6%). Thromboembolic events were mostly reported after the AstraZeneca vaccine (93.7%). Cerebral sinus thrombosis was the most common among thromboembolic events reported after the AstraZeneca vaccine. Among the reported cases, mortality was noted in 29.9% patients. CONCLUSIONS: Thromboembolic events can occur after COVID-19 vaccination, most commonly after the AstraZeneca vaccine. Cerebral sinus thrombosis is the most common manifestation noted in vaccinated individuals.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Mani A, Ojha V. Thromboembolism after COVID-19 Vaccination: A Systematic Review of Such Events in 286 Patients. Ann Vasc Surg. 2022. PMID: 35568325. doi:10.1016/j.avsg.2022.05.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。